How Metformin, Glimepiride and Dapagliflozin Help Manage Type 2 Diabetes

GLIDAPAFLOZIN TRIO is a prescription-only triple fixed-dose combination tablet used in adults with type 2 diabetes mellitus whose blood sugar is not controlled on two or more of its ingredients. It combines Dapagliflozin 10mg (an SGLT2 inhibitor), Glimepiride (a sulfonylurea, usually 1mg or 2mg) and Metformin Hydrochloride Prolonged Release (a biguanide, usually 500mg or 1000mg). Three different mechanisms work together, in one tablet, to lower blood glucose and reduce the number of pills a patient has to take each day.

Product Overview

The GLIDAPAFLOZIN TRIO range is built for people with type 2 diabetes who need more than one medicine to reach their HbA1c target. The range includes:

GLIDAPAFLOZIN TRIO 1 FORTE
GLIDAPAFLOZIN TRIO 2
GLIDAPAFLOZIN TRIO 2 FORTE

Each variant contains the same three drug classes in different strength combinations. For example, the main composition types are Dapagliflozin 10mg + Glimepiride 2mg + Metformin Hydrochloride 500mg, and Dapagliflozin (10mg) + Glimepiride (2mg) + Metformin Hydrochloride (1000mg) (Extended Release). Always check the strip or carton for the exact strength of the variant you have been prescribed, because the strength on the label decides your dose.

The metformin component is a prolonged release (PR) or extended release (ER) form, which releases the drug slowly over several hours. This usually means better stomach tolerance than plain metformin tablets and once-daily or twice-daily dosing as your doctor decides.

Composition and How Each Ingredient Works

1. Dapagliflozin 10mg (SGLT2 inhibitor)

Dapagliflozin blocks the sodium-glucose co-transporter 2 (SGLT2) in the proximal tubules of the kidney. Normally the kidney reabsorbs most of the filtered glucose back into the blood. By blocking SGLT2, dapagliflozin makes the body remove extra glucose through urine. This action is independent of insulin, so it keeps working even when beta-cell function declines. Because it removes glucose and some sodium and water, it can also produce modest weight loss and a small drop in blood pressure.

1. Glimepiride (2mg or 1mg) (sulfonylurea)

Glimepiride stimulates the beta cells of the pancreas to release more insulin. It is a long-acting, once-daily sulfonylurea. Glimepiride tablets IP in 1mg, 2mg, 3mg and 4mg strengths are widely used in India as an add-on to metformin.

1. Metformin Hydrochloride Prolonged Release (500mg or 1000mg) (biguanide)

Metformin lowers glucose production by the liver, improves insulin sensitivity in muscle and fat, and slightly reduces glucose absorption in the gut. It is the first-line oral drug for type 2 diabetes in most national and international guidelines. Metformin does not usually cause hypoglycaemia on its own and is generally weight-neutral.

Together, these three drugs attack high blood sugar from the kidney, the pancreas and the liver or muscle, which is why a triple combination can achieve additive glucose-lowering.

Indications: What Is GLIDAPAFLOZIN TRIO Used For?

GLIDAPAFLOZIN TRIO tablets are indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus who are:

Not adequately controlled on metformin and glimepiride together
Not adequately controlled on metformin and dapagliflozin together
Already taking the three individual drugs and who may switch to one fixed-dose tablet

This is not a first-line starting treatment and it is not meant for type 1 diabetes or for treating diabetic ketoacidosis. Doctors usually prescribe it only after dual therapy fails to achieve the target.

Metformin Tablet Uses and Metformin Hydrochloride Tablet Uses

Metformin hydrochloride tablet uses include:

Lowering blood glucose in type 2 diabetes, alone or with other antidiabetic medicines
Reducing insulin resistance
Helping prevent or delay type 2 diabetes in selected people with prediabetes, as advised by a doctor
Being used by doctors, in some cases, in polycystic ovary syndrome (PCOS), although this is an off-label use that only a doctor should decide

In a prolonged release tablet, metformin hydrochloride is released gradually, which can lower the chance of nausea, diarrhoea and abdominal discomfort. Metformin hydrochloride prolonged release and glimepiride tablets IP, as a two-drug combination, have been used in India for years, and the triple combination adds dapagliflozin to that foundation.

Dapagliflozin 10 mg Uses

Dapagliflozin 10 mg is the standard dose used in adults. Dapagliflozin 10 mg uses include:

Improving glycaemic control in adults with type 2 diabetes, alone or added to other medicines
Reducing the risk of hospitalisation for heart failure in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors
Treating heart failure with reduced ejection fraction, in adults with or without diabetes
Slowing the decline of kidney function in chronic kidney disease, in selected adults

Please note that the heart failure and kidney indications belong to the single-ingredient dapagliflozin product. In a triple combination tablet, the approved labelled indication is for blood glucose control in type 2 diabetes. Your doctor decides whether the extra heart or kidney benefits are relevant to you.

Glimepiride Tablet Uses

Glimepiride tablet uses include controlling blood sugar in adults with type 2 diabetes when diet, exercise and weight reduction alone are not enough. It can be used alone or with metformin or insulin. Glimepiride tablets IP 1mg is often the starting strength in patients who are older, have kidney problems or have a higher hypoglycaemia risk, and the dose is titrated slowly by the doctor. Glimepiride uses are restricted to type 2 diabetes. It does not work in type 1 diabetes.

Efficacy and Clinical Evidence

Evidence for the three ingredients is strong, although the best data come from the individual drugs and from dual combinations. This is how the evidence reads:

Metformin: The UK Prospective Diabetes Study (UKPDS 34) showed that metformin reduced diabetes-related complications and all-cause mortality in overweight patients with newly diagnosed type 2 diabetes. This remains one of the most cited trials supporting metformin as a first-line drug.

Dapagliflozin as add-on to metformin: In a 24-week randomised, placebo-controlled trial (Bailey et al., Lancet 2010), adding dapagliflozin to metformin produced a significant reduction in HbA1c, fasting plasma glucose and body weight compared with placebo. A 52-week study (Nauck et al., Diabetes Care 2011) compared dapagliflozin and glipizide added to metformin. HbA1c reductions were similar, but dapagliflozin produced weight loss and far fewer hypoglycaemic episodes.

Dapagliflozin and cardiovascular outcomes: The DECLARE-TIMI 58 trial showed that dapagliflozin lowered the combined risk of hospitalisation for heart failure and cardiovascular death in patients with type 2 diabetes. DAPA-HF and DAPA-CKD added evidence for heart failure and chronic kidney disease outcomes respectively.

Glimepiride: Clinical studies show glimepiride reduces HbA1c effectively, both alone and combined with metformin. Its once-daily dosing and a more favourable cardiovascular safety profile than older sulfonylureas have been supported by trials such as CAROLINA, which found glimepiride was non-inferior to linagliptin for major cardiovascular events, though it did cause more hypoglycaemia and weight gain.

Triple therapy: Studies of dapagliflozin added to metformin plus a sulfonylurea (Matthaei et al., 2015) showed a further HbA1c reduction and weight loss compared with placebo. Real-world Indian data on fixed-dose triple combinations of this type generally report good HbA1c improvement and better adherence, although the data come largely from observational studies and not from large outcome trials of the exact fixed-dose product.

Honest note: no single trial studies the exact branded tablet GLIDAPAFLOZIN TRIO against every alternative. The evidence is built on the proven efficacy of each component and on bioequivalence of fixed-dose combinations.

Key Benefits of GLIDAPAFLOZIN TRIO

Triple-action glucose control: kidney, pancreas and liver/muscle are all targeted.
Fewer tablets: one tablet replaces three, which supports adherence, and better adherence tends to give better long-term control.
Weight and blood pressure: dapagliflozin may lead to modest weight loss and a mild blood pressure reduction. This offsets the weight gain sometimes seen with glimepiride.
Prolonged release metformin: better gastrointestinal tolerance and convenient dosing.
Low insulin dependence of the SGLT2 effect: it works even in advanced disease, where the pancreas produces less insulin, within the limits of kidney function.
Cost convenience: a single fixed-dose pack is often more economical than buying three separate medicines.

Dosage and How to Take

Take the tablet exactly as your doctor prescribes. In general:

Swallow whole with water. Do not crush, chew or break prolonged release tablets.
Take with or just after a meal (usually breakfast, or breakfast and dinner as directed) to reduce stomach upset and the risk of low blood sugar.
Do not skip meals after taking the tablet, because glimepiride can cause hypoglycaemia if you do.
Drink enough fluids unless your doctor has restricted them.
Do not stop or change the dose without medical advice.

Doctors choose between TRIO 1 FORTE, TRIO 2 and TRIO 2 FORTE depending on your current glycaemic control, kidney function, age and risk of hypoglycaemia.

Side Effects

Common: nausea, diarrhoea, abdominal discomfort, increased urination, genital fungal infections, urinary tract infections, headache, dizziness, mild weight loss.
Hypoglycaemia (glimepiride-related): shakiness, sweating, hunger, confusion, palpitations. Keep a sugar source handy.
Serious but rare: lactic acidosis (metformin), diabetic ketoacidosis including euglycaemic DKA (dapagliflozin), severe dehydration, low blood pressure, kidney problems, and a rare serious genital infection called Fournier’s gangrene. Seek emergency care if you have severe stomach pain, rapid breathing, unusual tiredness, vomiting, or pain and swelling around the genital area with fever.

Precautions and Who Should Avoid It

Do not use this tablet if you have type 1 diabetes, diabetic ketoacidosis, severe kidney impairment (the glucose-lowering effect of dapagliflozin falls with reduced kidney function, and metformin is contraindicated at eGFR below 30), serious liver disease, or a known allergy to any ingredient.
Tell your doctor if you are pregnant, planning pregnancy or breastfeeding. The combination is generally not recommended in these situations.
Stop the medicine and consult your doctor before surgery, contrast dye scans, or if you have severe vomiting, diarrhoea or poor fluid intake.
Alcohol raises the risk of hypoglycaemia and lactic acidosis. Avoid heavy drinking.
Inform your doctor about all medicines you take, including insulin, other antidiabetics, diuretics and blood pressure drugs.
Older patients may need closer monitoring for dehydration and low blood sugar.

Storage

Store below 30°C in a cool, dry place, away from light and out of the reach of children. Always check the pack for the manufacturer’s storage instructions.

Frequently Asked Questions

1. What is GLIDAPAFLOZIN TRIO tablet used for?
   It is used to control blood sugar in adults with type 2 diabetes who are not adequately controlled on dual therapy. It contains dapagliflozin, glimepiride and metformin hydrochloride prolonged release.
2. What is the difference between GLIDAPAFLOZIN TRIO 2, TRIO 2 FORTE and TRIO 1 FORTE?
   They contain the same three drug types but in different strength combinations, such as Glimepiride 1mg or 2mg and Metformin 500mg or 1000mg alongside Dapagliflozin 10mg. Check the label for the exact strength, and let your doctor choose the right one.
3. What is Dapagliflozin 10mg Glimepiride 2mg Metformin Hydrochloride 500mg used for?
   This combination is used for type 2 diabetes mellitus when blood sugar remains high on metformin with either dapagliflozin or glimepiride.
4. What does dapagliflozin do in the body?
   It blocks SGLT2 in the kidneys so that excess glucose leaves the body in the urine, which lowers blood sugar levels.
5. What are dapagliflozin 10 mg uses?
   Mainly type 2 diabetes. The standalone drug is also used for heart failure and chronic kidney disease in selected patients, as decided by a doctor.
6. What are metformin tablet uses?
   Metformin lowers blood glucose in type 2 diabetes by reducing liver glucose output and improving insulin sensitivity. Doctors sometimes use it in prediabetes and PCOS in specific cases.
7. What are glimepiride tablet uses?
   Glimepiride helps the pancreas release more insulin and is used to treat type 2 diabetes along with diet and exercise.
8. What is the difference between metformin prolonged release and normal metformin?
   Prolonged release tablets release the drug slowly over time, which usually causes fewer stomach side effects and allows less frequent dosing.
9. Can GLIDAPAFLOZIN TRIO cause low blood sugar?
   Yes, because it contains glimepiride. Hypoglycaemia is more likely if you skip meals, exercise heavily, drink alcohol or take other glucose-lowering drugs.
10. Can it help with weight loss?
    Dapagliflozin may cause modest weight loss, but this tablet is not a weight loss medicine and should not be used for that purpose.
11. When should I take this tablet, before or after food?
    It is usually taken with or just after a meal, as directed by your doctor.
12. What are the common side effects of dapagliflozin, glimepiride and metformin tablet?
    Common ones are nausea, diarrhoea, increased urination, genital or urinary infections, dizziness and low blood sugar.
13. Who should not take this tablet?
    People with type 1 diabetes, diabetic ketoacidosis, severe kidney or liver disease, pregnant or breastfeeding women, and anyone allergic to the ingredients should avoid it.
14. Is it safe in kidney disease?
    Not in severe kidney impairment. The doctor checks eGFR before and during treatment and may stop or change the medicine if kidney function drops.
15. Can I drink alcohol while taking it?
    It is best to avoid alcohol, since it raises the risk of both hypoglycaemia and lactic acidosis..

Conclusion

GLIDAPAFLOZIN TRIO 2, GLIDAPAFLOZIN TRIO 2 FORTE and GLIDAPAFLOZIN TRIO 1 FORTE bring together dapagliflozin, glimepiride and metformin hydrochloride prolonged release in a single tablet for adults with type 2 diabetes who need triple therapy. The combination uses three complementary mechanisms, helps reduce pill burden and may support weight and blood pressure benefits through dapagliflozin. Like any diabetes medicine, it needs the right patient selection, regular monitoring of blood sugar, HbA1c and kidney function, and awareness of hypoglycaemia and dehydration risks. This is a prescription-only medicine, and your doctor should always decide the right strength and dose. This article is for information only and does not replace medical advice.

For Further Information:  

Mail Us: contact@sterispharma.com or info@sterispharma.com

Call Now: +91 8824175417, +91 9982524671

Buy Now